异甘草素联合奥希替尼对肺癌患者血清脂肪因子水平的影响

The influence of isoglycyrrhizin combined with ochitinib on serum adipokine levels in lung cancer patients

目的研究异甘草素联合奥希替尼对肺癌患者血清脂肪因子水平的影响。方法选取2017年1月~2019年12月住院治疗的80例肺癌患者为研究对象,随机分为试验组(n=40)与对照组(n=40)。对照组给予奥西替尼治疗,试验组给予奥西替尼联合异甘草素治疗。比较两组患者治疗前后血清脂肪因子表达水平的变化,分析两组患者临床疗效和不良反应的发生率。结果试验组总有效率明显高于对照组(P<0.05);治疗前,两组患者血清瘦素、脂联素、生长素释放肽表达水平差异无统计学意义(P>0.05);治疗后,两组患者血清中瘦素、脂联素、生长素释放肽表达水平均明显降低(P<0.05),且试验组降低更明显;试验组不良反应发生率明显低于对照组,差异有统计学意义(P<0.05)。结论异甘草素联合奥希替尼对肺癌患者的临床疗效显著,能够有效降低患者血清脂肪因子水平,不良反应少,安全性高。

Objective To investigate the effect of isoglycyrrhizin combined with ochitinib on serum adipokine levels in lung cancer patients.Methods From January 2017 to December 2019,80 patients with lung cancer hospitalized in our hospital were randomly divided into the experimental group(n=40)and the control group(n=40).The control group was treated with oxitinib,and the experimental group was treated with oxitinib combined with isoglycan.The changes of serum adipokine expression level before and after treatment were compared,and the clinical efficacy and the incidence of adverse reactions were analyzed.Results The total effective rate of the experimental group was significantly higher than that of the control group(P<0.05);before treatment,there was no significant difference in the expression level of serum leptin,adiponectin and auxin releasing peptide between the two groups(P>0.05);after treatment,the expression level of serum leptin,adiponectin and auxin releasing peptide in the two groups was significantly decreased(P<0.05),and was more obvious in the experimental group;the incidence of adverse reactions was significantly lower than that in the control group(P<0.05).Conclusion Isoglycoside combined with ochitinib has a significant clinical effect on lung cancer patients,which can effectively reduce the serum adipokine level of patients,with less adverse reactions and high safety.